Page 26 - 2022_01-Haematologica-web

G. Cartron and J. Trotman
efficacy and safety. J Clin Oncol. 2018;36
(23):2395-2404.
65.Dreyling M, Ghielmini M, Rule S, et al.
Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guide- lines for diagnosis, treatment and follow-up. Ann Oncol. 2020;32(3):298-308.
66. Shenoy P, Sinha R, Tumeh JW, et al. Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits? Clin Lymphoma Myeloma Leuk. 2010;10(4):270-277.
67. Goldman MX, Mao JJ, Strouse CS, et al. Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer. 2021;127(18):3390- 3402.
68. Bhaskaran K, Bacon S, Evans SJ, et al. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and
linked national death registrations within the OpenSAFELY platform. Lancet Reg Health Eur. 2021;6:100109.
69. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors asso- ciated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737-747.
70. Thakkar A , Pradhan K, Shawn Jindal S, et al. Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy. Nature Cancer. 2021;2:392-399.
71. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood.2021;137(23):3165-3173.
72. Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clini- cal use: thought for the best use? Crit Rev
Oncol Hematol. 2007;62(1):43-52.
73. Dunleavy K, Hakim F, Kim Hk, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeosta-
sis. Blood. 2005;106(3):795-802.
74.Lamure S, Dulery R, Di Blasi R, et al.
Determinants of outcome in Covid-19 hos- pitalized patients with lymphoma: a retro- spective multicentric cohort study. EclinicalMedicine. 2020;27:100549.
75. Bachy E, Cerhan JR, Salles G. Early progres- sion of disease in follicular lymphoma is a robust correlate but not a surrogate for over- all survival. Blood Adv. 2021;5(6):1729-1732.
76. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32 (27):3059-3067.
18
haematologica | 2022; 107(1)